Centrus Energy Corp.

The landmark HALEU fuel deal with Oklo and a $1 billion+ DOE contract anchor Centrus's long-dated commercial-scale enrichment buildout. Analysts at Needham, B. Riley, and BofA cite Centrus's unique domestic positioning as a catalyst for re-rating and durable commercial earnings power over the coming years.

Execution and schedule risk on a long-dated enrichment capacity buildout remain the primary concern. Delays, cost inflation, or contracting changes can rapidly erode investor confidence, and results are highly path-dependent, making the timeline to commercial-scale HALEU production deeply uncertain.

Despite recent price swings, the analyst consensus remains a 'Moderate Buy' with an average 1-year price target of ~$265, representing roughly 70% upside from recent levels. Improving earnings estimate revisions and Centrus beating Q1 EPS estimates by $0.72 support a case for meaningful re-rating.

The stock has hit a 52-week low of $144.03, declining 41% over the past year and 56% over six months. InvestingPro's Fair Value analysis flags the stock as overvalued at current levels, and valuation compression risk looms if earnings normalize lower or investors rotate away from nuclear-fuel-cycle themes.

BofA Securities initiated coverage with a Buy rating, explicitly stating Centrus stands to benefit from nuclear growth and a U.S. supply shift. William Blair and Evercore ISI also initiated at Outperform, underscoring broad conviction that domestic policy tailwinds uniquely favor Centrus as the primary U.S. enrichment provider.

UBS maintained a Neutral rating while cutting its price target from $195 to $170, and JPMorgan initiated coverage at Neutral with a conservative $148 target. These analysts reflect skepticism that policy-driven demand will translate into durable, near-term commercial earnings given competitive and geopolitical uncertainties.